Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib for Steroid-refractory GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of graft-versus-host disease established based on tissue biopsy~* Steroid-refractory acute or chronic graft-versus-host disease according to EBMT/ELN criteria (T. Ruutu et al, 2014)~* Age 1 to 70 years~* Karnofsky index \>30%.~* Ability for oral drug intake~* Life expectancy \> 1 month~* Signed informed consent~Exclusion Criteria:~* Severe organ dysfunction: AST or ALT \>5 upper normal limits (excluding cases related to liver GVHD), creatinine \>2 upper normal limits~* Requirement for vasopressor support at the time of enrollment~* Uncontrolled bacterial or fungal infection at the time of enrollment~* Pregnancy~* Somatic or psychiatric disorder making the patient (or legal guardian) unable to sign informed consent

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib treatment (Type: EXPERIMENTAL): Ruxolitinib 10 mg bid for adults and children with body weight \> 40 kg, 0.15 mg/kg bid for children with body weight \< 40 kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).